Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations

T. M. Becker*, H. Rizos, A. De La Pena, I. A. Leclercq, S. Woodruff, R. F. Kefford, G. J. Mann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


The cyclin-dependent kinase inhibitor p16INK4a has been identified as tumor suppressor and melanoma predisposition gene. While its cell cycle inhibitory ability is important in protecting cells from uncontrolled growth and possible tumor formation, other functions of p16INK4a are likely to contribute to its nature as a tumor suppressor. p16INK4a binding and inhibition of the transcription factor NF-κB has been shown and is consistent with the reports of abnormally increased NF-κB activity in various cancers including melanoma. Here, we present evidence that wild type p16INK4a binds to the NF-κB subunit RelA more efficiently than melanoma-associated p16INK4a mutations. Furthermore, whereas wild type p16INK4a strongly inhibits NF-κB transcriptional activity, a subset of melanoma-associated p16INK4a mutants show reduced NF-κB inhibitory function. p16INK4a does not affect NF-κB nuclear translocation or DNA binding, suggesting a mechanism that reduces NF-κB transactivation activity.

Original languageEnglish
Pages (from-to)873-879
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number3
Publication statusPublished - 8 Jul 2005
Externally publishedYes


  • Cell cycle
  • NF-κB
  • p16INK4a
  • Transcription factor
  • Tumor suppressor


Dive into the research topics of 'Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations'. Together they form a unique fingerprint.

Cite this